NVO - Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy Study Finds | Benzinga
A new observational study has identified a potential link between Novo Nordisk A/S’s (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss.
NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain.
Also Read: Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs.
The study revealed that individuals with diabetes who received and filled a semaglutide prescription were over four ...